Local firm signs tech-transfer agreement to manufacture oral cholera vaccines

 

Local firm signs tech-transfer agreement to manufacture oral cholera vaccinesDEK Vaccines 

Limited has partnered two vaccine manufacturing giants – IVI Korea and EuBiologics – to manufacture and distribute oral cholera vaccines in the country. The three parties made the tech-transfer signing official during a brief ceremony at the National Vaccines Institute in Accra.

The tech-transfer entails collaboration among the parties. Under it, IVI Korea is the IP holder, EuBiologics the bulk manufacturer and DEK Vaccines Limited is the ‘fill and finish’ partner in the biotechnology and pharmaceutical industry. The move is aimed at increasing global vaccines production capacity and reducing disparities in vaccines-access in African.

Speaking at the signing ceremony, Dr. Kofi Nsiah-Poku, Chief Executive Officer-DEK Vaccines Limited, intimated that this initiative marks the beginning of a promising journey toward technological advancement and collaboration for vaccines-manufacturing in Ghana, West Africa and Africa at large. He further noted that its success hinges on dedication, hard work, political will and commitment to making Africa a better and safer place.

“The transfer of technology to manufacture oral cholera vaccines (OCV) in Ghana is a bridge that connects Asia to Africa. It is a testament to the strength of collaboration, whereby individuals and organisations come together to share their expertise, knowledge and resources for the greater good.

“Let us remember that it is not just about technology; it is about the people – the minds and the hearts – that drive innovation forward. It is about potential to change lives, create new opportunities and solve some of the world’s most pressing challenges,” he added.

For her part, Rachel Park of EuBiologics expressed optimism about the initiative and her outfit’s readiness to further expand the partnership to other areas. “We’re pleased to be collaboratiing with DEK for oral cholera vaccines, and we believe that this is a starting point. We are looking forward to a successful commercialization of oral cholera vaccine and expanding our partnership to other pipelines,” she said.

IVI Korea’s representative, Andrea Kim, also assured of her firm’s readiness to contribute in the manufacture of high-quality vaccines for Ghana and Africa. Chief Executive Officer of the Food and Drugs Authority (FDA), Dr. Delese Mimi Darko, noted that the Authority will ensure the quality of vaccines produced will be up to standard.

“FDA’s role is to look at the protocol for the technology transfer, and we will make sure that everything is done in accordance with good manufacturing practices and guidelines,” she stated. In a speech delivered on his behalf, Minister of Health, Kwaku Agyemang Manu, pledged government’s support for the initiative and called on other capable private entities to venture into the vaccines-manufacturing space.

In a major advance in the fight against cholera outbreaks around the world, a local firm recently entered into a landmark technology transfer agreement to produce oral cholera vaccines. This exciting development not only has the potential to save countless lives, but also highlights the importance of technology transfer in the pharmaceutical industry. In this article, we will dive into the details of this agreement and its implications, while optimizing it for relevant search engines.

Understanding cholera: a global threat

Cholera remains a major public health problem, particularly in regions with inadequate sanitation and clean water resources. This water-borne disease, caused by the bacterium Vibrio cholerae, can spread quickly and cause severe dehydration, leading to death if left untreated. Vaccination is a critical tool for controlling cholera outbreaks, making the production of oral cholera vaccines a vital effort.

A local firm's commitment to global health

A renowned pharmaceutical player has demonstrated its commitment to global health by entering into a technology transfer agreement for the production of oral cholera vaccines. This step is not only a testament to their dedication, but also a strategic step to address health disparities on a global scale.

Technology Transfer Agreement

The technology transfer agreement he signed involves the exchange of knowledge, processes and expertise between the original vaccine manufacturer. This knowledge transfer will enable replication of the vaccine manufacturing process and ensure increased availability of these life-saving vaccines in regions most affected by cholera outbreaks. Now let's optimize this article with relevant information to ensure it reaches the right audience and ranks well in the search engines:

Oral Cholera Vaccine: This is essential because it directly relates to the main topic of the article. Tech-Transfer Agreement: Emphasizing this term emphasizes the importance of knowledge exchange in pharmaceutical manufacturing. Local pharmaceutical company: Mentioning the local nature of the company helps target readers interested in regional developments.

Global Health Initiatives: This underscores the firm's commitment to addressing global health challenges. Preventing Cholera Outbreaks: This phrase tells about the purpose of the vaccine and its role in preventing cholera outbreaks. Vibrio Cholerae Bacteria: This keyword may attract readers looking for detailed information on the causative agent of cholera.

The way forward

The technology transfer agreement between and the original vaccine manufacturer is undoubtedly a promising development in the fight against cholera. It paves the way for increased vaccine production, wider distribution, and ultimately the potential to save countless lives. Given the ongoing concerns about global health, the importance of such agreements and initiatives cannot be overstated.

In summary, the recent technology transfer agreement for the production of oral cholera vaccines is a significant step towards addressing cholera outbreaks worldwide. With a commitment to improving global health and imparting fundamental knowledge of vaccine production, she is poised to make a significant impact on cholera prevention. As we continue to monitor these developments, the potential to save lives and reduce the global burden of cholera remains within reach.

In a groundbreaking development for public health, a local firm recently signed a technology transfer agreement that paves the way for domestic production of oral cholera vaccines. This major step not only holds great promise for the fight against cholera on a global scale, but also represents a remarkable achievement for the local pharmaceutical industry. In this article, we delve into the details of this remarkable technology transfer agreement and the potential impact it could have on the fight against cholera.

Importance of oral cholera vaccines

Cholera is a water-borne disease that poses a serious threat to public health, especially in regions with poor sanitation and insufficient access to clean drinking water. The development and availability of oral vaccines against cholera have contributed to the reduction of morbidity and mortality associated with this infectious disease. These vaccines are considered an essential tool in the prevention and control of cholera, especially during outbreaks and in endemic areas.